AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Zacks Investment Research on MSN
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...
Shares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and ...
Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...
A Manhattan federal jury found Merck & Co. discriminated against a director of compliance and risk management by terminating ...
De Soto planners have delayed approval of Merck Animal Health's site plan to review fire lane and traffic flow details for the animal vaccine maker's expansion.
Zacks Investment Research on MSN
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
Merck MRK continues to face challenges with Gardasil, its second-largest product, which is a vaccine approved for the ...
The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the ...
Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...
Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in the ...
On November 17, BofA analyst Tim Anderson raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) to $105 from $98 and ...
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results